Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency.
D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism; D001667:Binding, Competitive; D001692:Biological Transport; D001921:Brain / Q000378:metabolism; D002090:Butyrophenones / Q000378:metabolism; D002417:Cattle; D003986:Dibenzocycloheptenes / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006220:Haloperidol / Q000378:metabolism; D008024:Ligands; D008238:Lysergic Acid Diethylamide / Q000378:metabolism; D008566:Membranes / Q000378:metabolism; D008968:Molecular Conformation; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010640:Phenothiazines; D011807:Quinolizines / Q000378:metabolism; D051381:Rats; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D012701:Serotonin / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014150:Antipsychotic Agents; D002090:Butyrophenones; D003986:Dibenzocycloheptenes; D008024:Ligands; D018377:Neurotransmitter Agents; D010640:Phenothiazines; D011807:Quinolizines; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D008238:Lysergic Acid Diethylamide; D006220:Haloperidol; D004298:Dopamine